Send to

Choose Destination
Leuk Res. 2012 Mar;36(3):316-23. doi: 10.1016/j.leukres.2011.11.002. Epub 2011 Nov 29.

Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.

Author information

UR Biologie Moléculaire des leucémies et lymphomes, Faculté de Médecine de Sousse, Université de Sousse, Tunisia.


FLT3 internal tandem duplication (FLT3-ITD) is usually considered as a bad marker for minimal residual disease (MRD) follow-up in acute myeloid leukemia (AML). Our objective was to evaluate the suitability of FLT3-ITD as a target for MRD detection by real-time quantitative PCR, in comparison with two other molecular MRD markers, NPM1 mutation and WT1 overexpression, in 20 adult AML patients treated in Acute Leukemia French Association (ALFA) trials. Overall, these 3 MRD markers showed comparable kinetics in 17/20 (85%) cases. Furthermore, we found that FLT3-ITD MRD levels after induction chemotherapy are predictive of complete remission duration.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center